• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Contineum Therapeutics Inc.

    3/6/25 4:13:44 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTNM alert in real time by email
    S-8 1 cont20250221_s8.htm FORM S-8 cont20250221_s8.htm

     

     

    As filed with the Securities and Exchange Commission on March 6, 2025

     

    Registration No. 333-         

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Contineum Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of incorporation or organization)

    27-1467257

    (IRS Employer Identification No.)

     

    3565 General Atomics Court, Suite 200

    San Diego, CA

    (Address of Principal Executive Offices)

     

    92121

    (Zip Code)

     

     

    Contineum Therapeutics, Inc. 2024 Equity Incentive Plan

    Contineum Therapeutics, Inc. 2024 Employee Stock Purchase Plan

    (Full title of the plan)

     

     

    Carmine Stengone

    Chief Executive Officer and President

    Contineum Therapeutics, Inc.

    3565 General Atomics Court, Suite 200

    San Diego, CA 92121

    (Name and address of agent for service)

     

    (858) 333-5280

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Jeffrey C. Thacker
    Gunderson Dettmer Stough Villeneuve
    Franklin & Hachigian, LLP
    3570 Carmel Mountain Road, Suite 200
    San Diego, CA 92130
    (858) 436-8000
     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company" in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☒

    Smaller reporting company ☒

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     

    Explanatory Note

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed to register additional securities of the same class as other securities for which a Registration Statement on Form S-8 of Contineum Therapeutics, Inc. (the “Registrant”) relating to the same employee benefit plans is effective. The Registrant previously registered shares of Class A common stock, par value $0.001 per share (“Common Stock”), for issuance under the Registrant’s 2024 Equity Incentive Plan (the “2024 Plan”) and the Registrant’s 2024 Employee Stock Purchase Plan (the “2024 ESPP”) pursuant to the Registration Statements filed with the Securities and Exchange Commission (the “SEC”) on April 9, 2024 (File No. 333-278580) (the “Prior Registration Statement”). In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statement are incorporated herein by reference. The Registrant is registering an additional 1,292,727 shares of Common Stock under the 2024 Plan and an additional 258,545 shares of Common Stock under the 2024 ESPP, pursuant to the provisions of each respective plan which provide for annual automatic increases in the number of shares of Common Stock reserved and available for issuance on January 1, 2025.

     

    PART I

     

    Information Required in the Section 10(a) Prospectus

     

    The information specified in this Part I is omitted from this Registration Statement on Form S-8, or the Registration Statement, in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended, or the Securities Act. In accordance with the rules and regulations of the Securities and Exchange Commission, or the SEC, and the instructions to Form S-8, such documents are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

     

    PART II

     

    Information Required in the Registration Statement

     

    Item 3.   Incorporation of Documents by Reference

     

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the SEC:

     

     

    (a)

    the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 6, 2025; 

     

     

    (b)

    all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act of 1934, as amended (the “Exchange Act”) since the end of the fiscal year covered by the registrant document referred to in (a) above; and

     

     

    (c)

    the description of the Registrant’s Common Stock contained in the Registrant’s registration statement on Form 8-A (File No. 001-42001), filed by the Registrant with the SEC under Section 12(b) of the Exchange Act, on April 2, 2024, including any amendments or reports filed for the purpose of updating such description.

     

    All other reports and documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which de-registers all securities then remaining unsold shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents. The Registrant is not, however, incorporating any documents or information that the Registrant is deemed to furnish and not file in accordance with SEC rules. Any statement contained in a document incorporated or deemed incorporated by reference in this Registration Statement will be deemed modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document that also is deemed incorporated by reference in this Registration Statement modifies or supersedes that statement.

     

    Item 8.   Exhibits

     

    The following exhibits are incorporated herein by reference.

     

           

    Incorporated by Reference

      Filed

    Exhibit Number

     

    Description

     

    Form

     

    File No.

     

    Exhibit

     

    Filing Date

     

    Herewith

    4.1

     

    Form of Registrant’s Class A common stock certificate.

     

    S-1/A

     

    333-278003

     

    4.1

     

    04/01/2024

       

    4.2

     

    Amended and Restated Certificate of Incorporation of the Registrant.

     

    8-K

     

    001-42001

     

    3.1

     

    04/09/2024

       

    4.3

     

    Amended and Restated Bylaws of the Registrant.

     

    8-K

     

    001-42001

     

    3.2

     

    04/09/2024

       

    5.1

     

    Opinion and Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP.

                     

    X

    23.1

     

    Consent of Independent Registered Public Accounting Firm.

                     

    X

    23.2

     

    Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (contained in Exhibit 5.1).

                     

    X 

    24.1

     

    Power of Attorney (contained on the signature page hereto).

                     

    X 

    99.1

     

    2024 Equity Incentive Plan and forms of agreements thereunder.

     

    S-1/A

     

    333-278003

     

    10.3

     

    04/01/2024

     

     

    99.2

     

    2024 Employee Stock Purchase Plan.

     

    S-1/A

     

    333-278003

     

    10.4

     

    04/01/2024

     

     

    107

     

    Filing Fee Table.

                     

    X

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California on March 6, 2025.

     

      Contineum Therapeutics, Inc.
      By: /s/ Carmine Stengone                     
      Carmine Stengone
      President, Chief Executive Officer and Director

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Carmine Stengone and Peter Slover and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this registration statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorney-in-fact and agents or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    IN WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date indicated.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

    Title

    Date

         

    /s/ Carmine Stengone         
    Carmine Stengone

    President, Chief Executive Officer and Director
    (Principal Executive Officer)

    March 6, 2025

         

    /s/ Peter Slover         
    Peter Slover

    Chief Financial Officer
    (Principal Financial Officer and Principal Accounting Officer)

    March 6, 2025
         

    /s/ Evert Schimmelpennink         
    Evert Schimmelpennink

    Chairperson of the Board of Directors

    March 6, 2025
         

    /s/ Lori Lyons-Williams         
    Lori Lyons-Williams

    Director

    March 6, 2025
         

    /s/ Todd Brady         
    Todd Brady

    Director

    March 6, 2025
         

    /s/ Olivia Ware         
    Olivia Ware

    Director

    March 6, 2025
         

    /s/ Sarah Boyce         
    Sarah Boyce

    Director

    March 6, 2025
         

    /s/ Troy Ignelzi         
    Troy Ignelzi

    Director

    March 6, 2025

     

     
    Get the next $CTNM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTNM

    DatePrice TargetRatingAnalyst
    10/22/2024$32.00Outperform
    Robert W. Baird
    More analyst ratings

    $CTNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Contineum Therapeutics with a new price target

      Robert W. Baird initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $32.00

      10/22/24 6:13:41 AM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Contineum Therapeutics Inc.

      DEFA14A - Contineum Therapeutics, Inc. (0001855175) (Filer)

      4/29/25 4:14:06 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Contineum Therapeutics Inc.

      DEF 14A - Contineum Therapeutics, Inc. (0001855175) (Filer)

      4/29/25 4:07:27 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Contineum Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)

      4/28/25 4:10:35 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CTNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

      4/28/25 4:05:00 PM ET
      $CTNM
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. "We are excited to welcome Diego to our board," commented Eef Schimmelpennink, Contineum's Chairperson. "He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr.

      3/17/25 4:05:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18th at 12:30 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum's website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with s

      3/12/25 4:05:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Contineum Therapeutics Inc.

      SC 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)

      11/14/24 4:38:16 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Leadership Updates

    Live Leadership Updates

    See more
    • Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

      4/28/25 4:05:00 PM ET
      $CTNM
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. "We are excited to welcome Diego to our board," commented Eef Schimmelpennink, Contineum's Chairperson. "He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr.

      3/17/25 4:05:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

      SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe

      1/6/25 8:00:00 AM ET
      $CTNM
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CMO & Head of Development Watkins Tim

      4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      4/28/25 4:21:48 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Watkins Tim

      3 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      4/28/25 4:16:12 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Miralles Gines Diego

      4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      3/17/25 4:12:41 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care